2025-07-25 - Analysis Report
Okay, here's an analysis of Johnson & Johnson (JNJ) based on the provided information, presented in English with simplified data and concise analysis, as requested.

**Report: Johnson & Johnson (JNJ) Analysis**

Johnson & Johnson (JNJ) is a global healthcare company engaged in the research and development, manufacture, and sale of a broad range of products in the healthcare field.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return (JNJ):** 24.90%
*   **Cumulative Return (VOO):** 98.88%
*   **Performance Delta:** -73.4
*   **Relative Delta Percentile:** 9.3

**Analysis:** JNJ has significantly underperformed the S&P 500 over the period examined. The relative delta percentile indicates that this underperformance is near the lower end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta  | Cap(B) |
|------------|---------|--------|---------|-------|--------|
| 2015-2017  | 28.0%   | 56.1%  | -1.0%   | -0.0  | 336.2  |
| 2016-2018  | 8.0%    | 56.6%  | -10.0%  | 0.0   | 310.5  |
| 2017-2019  | 18.0%   | 56.6%  | -12.0%  | 0.7   | 351.0  |
| 2018-2020  | 12.0%   | 59.2%  | -8.0%   | 0.3   | 378.7  |
| 2019-2021  | 32.0%   | 59.6%  | -16.0%  | 0.2   | 411.6  |
| 2020-2022  | 7.0%    | 61.4%  | 5.0%    | 0.2   | 425.0  |
| 2021-2023  | -15.0%  | 61.4%  | -33.0%  | 0.4   | 377.1  |
| 2022-2024  | -35.0%  | 61.4%  | -61.0%  | 0.3   | 348.0  |
| 2023-2025  | -2.0%   | 70.1%  | -53.0%  | 0.2   | 408.0  |

**Analysis:** Over various 3-year periods, JNJ's alpha has generally been negative, indicating underperformance relative to its expected return based on its beta. Beta values are low, suggesting lower volatility than the market.  The MDD (Maximum Drawdown) values are high, indicating significant potential for loss during those periods. The CAGR has varied significantly.

**2. Recent Price Action**

*   **Current Price:** 169.56
*   **Previous Close:** 169.1
*   **Change:** 0.27
*   **5-Day Moving Average:** 166.93
*   **20-Day Moving Average:** 159.05
*   **60-Day Moving Average:** 155.43

**Analysis:** The price is above all three moving averages, suggesting a short-term upward trend. The small change from the previous close indicates recent stability.

**3. Market Risk Indicator & Technicals**

*   **Market Risk Indicator (MRI):** 0.3274 (Low Risk)
*   **RSI:** 78.62 (Overbought)
*   **PPO:** 0.81
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Recent (20-day) Relative Delta Change:** 7.1 (+) (Short-term Increase)
*   **Expected Return (%):** -291.8%

**Analysis:** The MRI suggests low market risk.  However, the RSI indicates that the stock is currently overbought, which could precede a pullback. The Hybrid Signal suggests buying, but with caution. The positive change in the relative delta over the past 20 days suggests a recent improvement in performance relative to the S&P 500, but the extremely negative expected return is a significant concern. The small change from the previous close indicates a lack of significant price movement today, not reflecting a major news event.

**4. Recent News & Significant Events**

*   **2025-07-23:** Major business developments, regulatory changes, or market events.
*   **2025-07-22:** Analyst discussions on performance and outlook.
*   **2025-07-24:** Notable stock volatility.
*   **2025-07-21:** Risks and opportunities highlighted by market experts.

**Analysis:** Recent news suggests that JNJ is experiencing volatility and is subject to analyst scrutiny. Investors should monitor news and company announcements closely.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출        |
|------------|------|-------------|
| 2025-07-24 | 2.3  | 23.74 B$    |
| 2025-04-23 | 4.57 | 21.89 B$    |
| 2024-10-23 | 1.12 | 22.47 B$    |
| 2024-07-25 | 1.95 | 22.45 B$    |
| 2025-07-24 | 1.95 | 22.45 B$    |

**Analysis:** The EPS and revenue figures have fluctuated over the past few quarters. It is imporatant to note there are duplicated values. Investors should examine the underlying factors causing these variations.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-03-31   | $21.89B   | 66.40%        |
| 2024-12-31   | $22.52B   | 68.35%        |
| 2024-09-30   | $22.47B   | 69.01%        |
| 2024-06-30   | $22.45B   | 69.40%        |
| 2024-03-31   | $21.38B   | 69.55%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-03-31   | $78.11B   | 14.08%   |
| 2024-12-31   | $71.49B   | 4.80%    |
| 2024-09-30   | $70.16B   | 3.84%    |
| 2024-06-30   | $71.54B   | 6.55%    |
| 2024-03-31   | $70.02B   | 4.65%    |

**Analysis:** While revenue has remained relatively stable, profit margins have shown a slight decline.  ROE (Return on Equity) has fluctuated, with a notable increase in the most recent quarter.  Equity has generally increased.

**7. Overall Summary**

JNJ has significantly underperformed the S&P 500.  Recent price action shows an upward trend, but the RSI suggests the stock is overbought.  The MRI indicates low market risk.  Financial data reveals relatively stable revenue but fluctuating profit margins and ROE. Recent news points to volatility and ongoing analyst evaluation. The extremely negative expected return warrants significant caution.

**Recommendation:**  Given the underperformance, overbought condition, and negative expected return, a cautious approach is warranted.  Further research into the reasons for the underperformance and negative outlook is strongly recommended before making any investment decisions. Pay close attention to upcoming news and analyst reports.
